Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension

European Respiratory Journal

Volumn 35, Issue 6, 2010, Pages 1286-1293

  Sztrymf, B ^a   Souza, R ^a   Bertoletti, L ^a   Jais X ^a   Sitbon, O ^a   Price, L C ^a   Simonneau, G ^a   Humbert, M ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Brain natriuretic peptide; Heart failure; Intensive care unit; Pulmonary arterial hypertension; Survival

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CATECHOLAMINE; CREATININE; DOBUTAMINE; ILOPROST; NITRIC OXIDE; NORADRENALIN; PROSTACYCLIN; SILDENAFIL; SODIUM; UNIPROST;

ACUTE HEART FAILURE; ADOLESCENT; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE COURSE; FEMALE; HEART RIGHT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INFECTION; INTENSIVE CARE UNIT; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SODIUM BLOOD LEVEL; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CREATININE; DOBUTAMINE; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; HYPERTENSION, PULMONARY; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SODIUM; SURVIVAL ANALYSIS; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 77953520985     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00070209     Document Type: Article

References (44)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527-1538.
2. Galie N, Rubin L. Pulmonary arterial hypertension. Epidemiology, pathobiology, assessment and therapy. J Am Coll Cardiol 2004; 43: S1-S90.
3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for thromboembolic disease. Chest 2008; 133: 454S-545S.
4. McNeil K, Dunning J, Morrell NW. The pulmonary physician in critical care. 13: the pulmonary circulation and right ventricular failure in the ITU. Thorax 2003; 58: 157-162.
5. Zamanian RT, Haddad F, Doyle RL, et al. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007; 35: 2037-2050.
6. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle. Chest 2005; 128: 1836-1852.
7. Kerbaul F, Rondelet P, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34: 2814-2819.
8. Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466-475. (Pubitemid 9006974)
9. Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure-load induced right ventricular failure. Crit Care Med 2004; 32: 1035-1040.
10. Rattes M, Calvin JE. Acute pulmonary hypertension. In: Pinsky MR, Dhainaut JF, eds. Pathophysiologic Foundations of Critical Care. Baltimore, Williams and Wilkins, 1993; pp. 312-336.
11. Sztrymf B, Humbert M. Practical management of pulmonary arterial hypertension in the intensive care unit. In: Humbert M, Lynch III JP, eds. Pulmonary Hypertension. Informa Heathcare USA, New York, 2009; pp. 455-461.
12. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-2963.
13. Kurzyna M, Zyłkowska J, Fijałkowska A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol Pol 2008; 66: 1033-1039.
14. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736.
15. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
16. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal Brain ntriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313-1321.
17. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107: 2545-2547.
18. Pieralli F, Olivotto I, Vanni S, et al. Usefulness of bedside testing for brain natriuretic peptide to identifie right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97: 1386-1390.
19. Adachi S, Ito H, Ohta Y, et al. Distribution of mRNAs natriuretic peptides in right ventricular hypertrophy after pulmonary arterial banding. Am J Physiol 1995; 268: H162-H169.
20. Souza R, Bogossian HB, Humbert M, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 2005; 25: 509-513.
21. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 401-409.
22. Torbicki A, Kurzyna M, Kuca P, et al. Detectable cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
23. Meyer T, Binder L, Hruska N, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36: 1632-1636.
24. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145: 821-825.
25. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
26. Kerbaul F, Brimioulle S, Rondelet B, et al. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med. 2007; 175: 846-850.
27. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
28. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
29. Pedemonte VO, Aránguiz Santander E, Torres H H, et al. [Right ventricular assistance with a centrifugal pump. Report of two cases]. Rev Mal Chil 2008; 136: 359-366.
30. Montani D, Jaïs X, Price LC, et al. Cautious use of epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34: 1348-1356.
31. Schrier RW. Water and sodium retention in oedematous disorders: role of vasopressin and aldosteron. Am J Med 2006; 119: S47-S53.
32. Damman K, Navis G, Smilde T, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878.
33. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium and outcome in patients hospitalized for heart failure: an analysis from the OPTIMIZEHF registry. Eur Heart J 2007; 28: 980-988.
34. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: 1364-1369.
35. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297: 1319-1331.
36. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double blind, randomized trial. Circulation 2003; 107: 2690-2696.
37. Shah SJ, Thenappan T, Rich S, et al. Association of serum creatinine with hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008; 117: 2475-2483.
38. Quark M, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.
39. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
40. Humbert M, Morrel NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S13-S24.
41. Sharma AC. Sepsis-induced myocardial dysfunction. Shock 2007; 28: 265-269.
42. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
43. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1034-1041.
44. Bossone E, Bodini BD, Mazza A, et al. Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005; 127: 1836-1843.